Drug intelligence / Profile preview

duloxetine + escitalopram

Development stage
Preclinical
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

Duloxetine + escitalopram is a combination of two antidepressant medications, each with distinct mechanisms of action. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI), while escitalopram is a selective serotonin reuptake inhibitor (SSRI). Both drugs increase the levels of serotonin in the brain, but duloxetine also increases norepinephrine. This combination may be considered in treatment-resistant cases of major depressive disorder or other psychiatric conditions where monotherapy has been insufficient. However, combining these agents significantly increases the risk for serotonin syndrome—a potentially life-threatening condition due to excessive serotonergic activity[1][3]. There are limited clinical studies on this specific combination; most evidence comes from case reports and small observational studies.

02

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on duloxetine + escitalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on duloxetine + escitalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call